James B. Yu

A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).

David C. Smith, N. Stambler, J. Sammon, 2014 .

Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists

C. Gross, R. Thompson, R. Karnes, 2014, Medical care.

Perceptions of radiation oncologists and urologists on sources and type of evidence to inform prostate cancer treatment decisions.

C. Gross, R. Karnes, J. Tilburt, 2014, International journal of radiation oncology, biology, physics.